Comparative Pharmacology
Head-to-head clinical analysis: BACIGUENT versus CENTANY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACIGUENT versus CENTANY.
BACIGUENT vs CENTANY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacitracin inhibits bacterial cell wall synthesis by dephosphorylating the lipid carrier that transports peptidoglycan precursors across the cell membrane, leading to accumulation of toxic intermediates and cell lysis.
Mupirocin binds to isoleucyl-tRNA synthetase, inhibiting bacterial protein synthesis.
Topical: Apply thin layer to affected area 1 to 3 times daily; maximum duration of therapy is 1 week.
Apply a thin layer to affected area twice daily for 10 days. For perioral dermatitis, apply once daily.
None Documented
None Documented
Terminal elimination half-life approximately 2.5–3.5 hours in adults with normal renal function; prolonged in renal impairment (up to 20–30 hours in anuria)
8-10 minutes in serum; prolonged to 15-20 minutes in patients with renal impairment. Clinical context: Rapidly cleared, infrequent dosing intervals (e.g., every 20 minutes during procedure).
Primarily renal excretion of unchanged drug via glomerular filtration and tubular secretion; >90% of absorbed dose recovered in urine within 24 hours; biliary/fecal elimination minimal (<2%)
Primarily excreted unchanged in urine via glomerular filtration and tubular secretion (85-90% renal); minor biliary/fecal elimination (<5%).
Category C
Category C
Topical Antibiotic
Topical Antibiotic